GLP1R and Hypoglycemia: Thanks to this initiative, it was demonstrated that novel drugs such as several glucagon-like peptide 1 receptor agonists (GLP-1RAs) and sodium-glucose co-transporter-2 inhibitors (SGLT-2is) not only improved glycemic control without causing hypoglycemia but also promoted weight loss and reduced CV and renal morbidity and mortality.